Indication Target/marker/pathway Summary Licensing status Publication and contact information
Bladder cancer Keratin 14 (KRT14) Patient sample studies suggest KRT14 could help predict bladder cancer prognosis. In two sets of gene and protein expression data from bladder cancer patient samples, KRT14 expression correlated with lower overall survival. Next steps include testing whether KRT14 can predict patient response to chemotherapy. SciBX 5(5); doi:10.1038/scibx.2012.118 Published online Feb. 2, 2012 Patent application filed; available for licensing Volkmer, J.-P. et al. Proc. Natl. Acad. Sci. USA; published online Jan. 19, 2012; doi:10.1073/pnas.1120605109 Contact: Keith S. Chan, Baylor College of Medicine, Houston, Texas e-mail: Contact: Irving L. Weissman, Stanford University, Stanford, Calif. e-mail: Contact: Debashis Sahoo, same affiliation as above e-mail:
Breast cancer IL-20 Studies in mice and in human samples suggest inhibiting IL-20 could help treat breast cancer and breast cancer-induced bone loss. In primary breast tumor samples, levels of IL-20 were inversely correlated with metastasis-free survival. In mice with mammary tumors, an anti-IL-20 antibody lowered tumor growth compared with control IgG. In mouse models of metastatic mammary cancer, the antibody decreased both the number of bone metastases and bone loss compared with control IgG. Ongoing work includes testing IL-20 inhibition in animal models of bone metastases of prostate and other cancers. NN8226 (anti-IL20), an anti-IL-20 mAb from Novo Nordisk A/S, is in Phase II testing to treat rheumatoid arthritis (RA). SciBX 5(5); doi:10.1038/scibx.2012.119 Published online Feb. 2, 2012 Patented by National Cheng Kung University; available for licensing Hsu, Y.-H. et al. J. Immunol.; published online Jan. 11, 2012; doi:10.4049/jimmunol.1102843 Contact: Ming-Shi Chang, National

Read the full 2795 word article

How to gain access

Continue reading with a
two-week free trial.